Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 4/20 | 0.58 |
| ▸ | GABRD | O14764 | 4/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.58 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.58 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.58 |
| ▸ | GABRE | P78334 | 4/20 | 0.58 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.58 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.58 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.58 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.58 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17712927 | 0.77 | GABRP (0.55) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL8072226 | 0.77 | GABRP (0.68) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL19808926 | 0.76 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31324958 | 0.75 | SOS2 (0.41) | CAMKK2CYP1A2SOS2ALDH1A1XDH | |
| SCHEMBL31253334 | 0.75 | SOS2 (0.41) | CAMKK2CYP1A2SOS2ALDH1A1XDH | |
| SCHEMBL838145 | 0.75 | ALDH1A1 (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL524642 | 0.74 | GABRP (0.69) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7651563 | 0.74 | GABRP (0.64) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20599509 | 0.74 | SMN1; SMN2 (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18611219 | 0.74 | GABRP (0.64) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1752455-B1 | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2010-11-10 | — | — | EP | disclosed |
| US-7807694-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2010-10-05 | — | — | US | disclosed |
| EP-1752455-A2 | Chemokine receptor binding heterocyclic compounds | ANORMED INC. (CA) | 2007-02-14 | — | — | EP | disclosed |
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-11-09 | — | — | US | disclosed |
| US-7091217-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2006-08-15 | — | — | US | disclosed |
| EP-1317451-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-08-09 | — | — | EP | disclosed |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-09-02 | — | — | US | disclosed |
| US-6734191-B2 | PREFERABLY TERTIARY AMINES COMPRISING TETRAHYDROQUINOLINE AND BENZIMIDAZOLE; USE TREATING HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND FELINE IMMUNODEFICIENCY VIRUS (FIV) | ANORMED, INC. (CA) | 2004-05-11 | — | — | US | disclosed |
| EP-1317451-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2003-02-06 | — | — | US | disclosed |
| WO-2002034745-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252795-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | GABRP 553/4885GABRD 519/4885GABRA1 886/4885 |
| US-20040171638-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | GABRP 553/4885GABRD 519/4885GABRA1 886/4885 |
| US-20030028022-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR3, CCR2 | GABRP 553/4885GABRD 519/4885GABRA1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.